Inflammatory Bowel Disease
Q&A: Integrative risk model may predict Crohn’s development in healthy at-risk individuals
A new integrative model demonstrated “strong predictive performance” in identifying future risk for Crohn’s disease development among healthy first-degree relatives of patients with CD, according to a researcher.
Tulisokibart bests placebo, may yield ‘important clinical benefit’ via TL1A blockade in UC
Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to a new study that also incorporated a predictive biomarker for response.
F. prausnitzii may serve as marker for thiamine response in quiescent IBD, chronic fatigue
An abundance of Faecalibacterium prausnitzii or Roseburia hominis may predict the effectiveness of high-dose thiamine treatment to alleviate chronic fatigue in quiescent inflammatory bowel disease, according to research.
A case of chronic diarrhea
A 65-year-old woman presents for evaluation of a 6-month history of chronic diarrhea. She has generally been healthy throughout her life.
Initial dose of infliximab 5 mg/kg ‘should be adequate’ in most cases of acute severe UC
No significant differences were reported in clinical response at day 7 between 5 mg/kg and 10 kg/kg doses of infliximab in acute severe ulcerative colitis, nor were there differences in intensified, accelerated or standard dosing at month 3.
After July surge, FDA approvals for GI settle into summer lull: What you may have missed
Following a July boom in game-changing FDA approvals for gastroenterology, including the first blood test for colorectal cancer, the agency has succumbed to the summer lull with only three approvals for GI to close out the season.
Early endoscopic response to Skyrizi induction linked to fewer hospitalizations in Crohn’s
Early endoscopic improvement after Skyrizi induction was associated with fewer Crohn’s disease-related hospitalizations and surgeries through 52 weeks of maintenance in patients with moderately to severely active disease, research showed.
Stay up to date: Healio recaps pivotal guidelines for GI, liver disease in 2024 (so far)
Tremfya nabs FDA approval for active ulcerative colitis, chasing competitor Skyrizi
The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release.
AGA: ‘Keep both patient and fetus safe’ when managing GI, liver diseases in pregnancy
Multidisciplinary care is key when managing patients with pregnancy-related gastrointestinal and liver diseases, with a “paramount goal” of keeping both the patient and the fetus safe, according to an AGA clinical practice update.